155 related articles for article (PubMed ID: 12134139)
21. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
Steffens MG; Oosterwijk E; Kranenborg MH; Manders JM; Debruyne FM; Corstens FH; Boerman OC
J Nucl Med; 1999 May; 40(5):829-36. PubMed ID: 10319758
[TBL] [Abstract][Full Text] [Related]
22. Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment.
Yoo TM; Chang HK; Choi CW; Webber KO; Le N; Kim IS; Eckelman WC; Pastan I; Carrasquillo JA; Paik CH
J Nucl Med; 1997 Feb; 38(2):294-300. PubMed ID: 9025758
[TBL] [Abstract][Full Text] [Related]
23. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
Siim BG; Laux WT; Rutland MD; Palmer BN; Wilson WR
Cancer Res; 2000 Aug; 60(16):4582-8. PubMed ID: 10969810
[TBL] [Abstract][Full Text] [Related]
24. Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting.
Liu G; Dou S; He J; Yin D; Gupta S; Zhang S; Wang Y; Rusckowski M; Hnatowich DJ
Appl Radiat Isot; 2006 Sep; 64(9):971-8. PubMed ID: 16730997
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics in mice of four oligomer-conjugated polymers for amplification targeting.
He J; Liu G; Zhang S; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2003 Dec; 18(6):941-7. PubMed ID: 14969606
[TBL] [Abstract][Full Text] [Related]
26. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.
Liu G; Dou S; Baker S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biol Ther; 2010 Oct; 10(8):767-74. PubMed ID: 21099368
[TBL] [Abstract][Full Text] [Related]
27. [The radiolabeling property of oligonucleotide with 99mTc using NHS-MAG3 as a chelator].
Zhang C; Tan TZ; Kuang AR; Li YC; Zheng JG; Pan WM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Mar; 35(2):169-71. PubMed ID: 15071906
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting.
Chen X; Dou S; Liu G; Liu X; Wang Y; Chen L; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2008 Aug; 19(8):1518-25. PubMed ID: 18646837
[TBL] [Abstract][Full Text] [Related]
29. Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys.
Müller C; Schibli R; Forrer F; Krenning EP; de Jong M
Nucl Med Biol; 2007 Aug; 34(6):603-8. PubMed ID: 17707799
[TBL] [Abstract][Full Text] [Related]
30. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.
Liu G; Dou S; Liu Y; Wang Y; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2011 Dec; 22(12):2539-45. PubMed ID: 21985267
[TBL] [Abstract][Full Text] [Related]
31. [Experimental study of 99mTc-antisense DNA for tumor imaging].
Fan C; Hnatowich DJ
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Oct; 24(5):1142-7. PubMed ID: 18027714
[TBL] [Abstract][Full Text] [Related]
32. Improved tumor localization with (strept)avidin and labeled biotin as a substitute for antibody.
Hnatowich DJ; Fritz B; Virzi F; Mardirossian G; Rusckowski M
Nucl Med Biol; 1993 Feb; 20(2):189-95. PubMed ID: 8448574
[TBL] [Abstract][Full Text] [Related]
33. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging.
Nock B; Nikolopoulou A; Chiotellis E; Loudos G; Maintas D; Reubi JC; Maina T
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):247-58. PubMed ID: 12552343
[TBL] [Abstract][Full Text] [Related]
34. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice.
Hnatowich DJ; Mardirossian G; Fogarasi M; Sano T; Smith CL; Cantor CR; Rusckowski M; Winnard P
J Pharmacol Exp Ther; 1996 Jan; 276(1):326-34. PubMed ID: 8558450
[TBL] [Abstract][Full Text] [Related]
35. Noninvasive imaging of human telomerase reverse transcriptase (hTERT) messenger RNA with 99mTc-radiolabeled antisense probes in malignant tumors.
Liu M; Wang RF; Zhang CL; Yan P; Yu MM; Di LJ; Liu HJ; Guo FQ
J Nucl Med; 2007 Dec; 48(12):2028-36. PubMed ID: 18006621
[TBL] [Abstract][Full Text] [Related]
36. In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles.
Wang Y; Liu X; Nakamura K; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2009 Oct; 24(5):573-8. PubMed ID: 19877887
[TBL] [Abstract][Full Text] [Related]
37. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.
Liu G; Dou S; Chen X; Chen L; Liu X; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2010 Dec; 25(6):757-62. PubMed ID: 21204772
[TBL] [Abstract][Full Text] [Related]
38. [Synthesis and animal imaging of 99mTc-hydrazinonicotinamide-folate as a new folate receptor-targeted tumor imaging agent].
Liu LQ; Wang SZ; Li F; Teng B; Wang KZ; Qiu FC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Dec; 28(6):786-9. PubMed ID: 17260467
[TBL] [Abstract][Full Text] [Related]
39. Nonspecific cellular accumulation of 99mTc-labeled oligonucleotides in culture is influenced by their guanine content.
Wang Y; Liu X; Zhang Y; Liu G; Rusckowski M; Hnatowich DJ
Nucl Med Biol; 2007 Jan; 34(1):47-54. PubMed ID: 17210461
[TBL] [Abstract][Full Text] [Related]
40. 99mTc-labeling of colchicine using [99mTc(CO)3(H2O)3]+ and [99mTc triple bond N]2+ core for the preparation of potential tumor-targeting agents.
Korde A; Satpati D; Mathur A; Mallia M; Banerjee S; Kothari K; Sarma HD; Choudhari P; Venkatesh M
Bioorg Med Chem; 2006 Feb; 14(3):793-9. PubMed ID: 16289854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
